brown adviceAn investment management company released its “Brown Advisory Mid-Cap Growth Strategy” fourth quarter 2025 investor letter. A copy of the letter may be downloaded here. The strategy lagged the Russell MidCap® Growth Index in the fourth quarter due to stock selection. Performance was in line with full year expectations. The firm believes the strategy underperformed in 2025 because it did not own Palantir Technologies Inc. (PLTR). The strategy focuses on achieving solid risk-adjusted returns by investing in high-quality compounders with fair valuations and market capitalizations between $2 billion to $50 billion at the time of purchase. Please review the strategy’s top five holdings to get an insight into their key picks for 2025.
In its fourth-quarter 2025 investor letter, Brown Advisory Mid-Cap Growth Strategy highlighted stocks like Medline Inc. (NASDAQ:).mdln). Medline Inc. (NASDAQ:MDLN) is a healthcare company that manufactures Med-Surg products for hospitals, surgery centers, physician offices, post-acute facilities and nursing home sites of care. Medline Inc. on March 23, 2026. (NASDAQ:MDLN) stock closed at $42.48 per share. Medline Inc. (NASDAQ:MDLN)’s one-month return was -15.02%, and shares were up 1.14% YTD. Medline Inc. (NASDAQ:MDLN) has a market capitalization of $34.479 billion.
Brown Advisory Mid-Cap Growth Strategy had the following to say regarding Medline Inc. (NASDAQ:MDLN) in its fourth quarter 2025 investor letter:
“After following the company for years, we bought shares of Medline Inc (NASDAQ:MDLN) IPO in the quarter and added to our position later. Medline is a differentiated business that provides exposure to both medical technology demand and provider volume through its vertically integrated manufacturing and distribution platform. “Data from its large-scale distribution business informs its high-margin manufacturing business, which is a key competitive advantage.”
Medline Inc. (NASDAQ:MDLN) is not on our list The 40 Most Popular Stocks Among Hedge Funds Arriving in 2026. According to our database, 58 hedge fund portfolios held Medline Inc. at the end of the fourth quarter. (NASDAQ:MDLN). While we consider Medline Inc. as an investment. (NASDAQ:MDLN)’s potential, we believe some AI stocks offer more potential and have less downside risk. If you’re looking for an extremely undervalued AI stock that could also significantly benefit from Trump-era tariffs and the onshoring trend, check out our free report. best short term ai stocks.